Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

NCT07619235 is registered in ClinicalTrials.gov with Xianglin Yuan as lead sponsor.

NCT NCT07619235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
Lead sponsor
Xianglin Yuan
Phase
Phase 4
Overall status
Recruiting
Start date
June 10, 2026
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc)